Cardiogenic Shock Program Continues to Achieve Outstanding Results
Behnam Tehrani, MD Co-Director, Cardiogenic Shock Program, IHVI Co-Director, Cardiac Catheterization Laboratories, Inova Fairfax Medical Campus Alexander Truesdell, MD Co-Director, Cardiogenic Shock Program Cardiogenic shock has long been associated with high rates of morbidity and mortality. It was not until the landmark SHOCK trial in 1999 that survival increased from 20 percent to 50 percent through early revascularization. Since then, however, no further improvements in short-term outcomes have been realized.